MURRIETA, CA -- (Marketwire) -- 08/18/08 -- CLX Medical, Inc. (OTCBB: CLXN), which isfocused on the launch and distribution of unique medical diagnostic testingproducts, today announced the release of the company's August 2008 investornewsletter, which highlights the company's recent announcement of a letterof intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroidstimulating hormone (TSH) screening device used for the detection ofhypothyroidism in adults, a common thyroid disease.A PDF version of the August 2008 newsletter can be viewed on the company'scorporate website at http://www.clxmedical.com/newsletters.php.
With the letter of intent announced, CLX will now proceed toward adefinitive agreement for the acquisition of ThyroTest®, which would bepositioned in a wholly owned subsidiary of CLX Medical. ThyroTest® isFDA cleared and has also achieved CLIA waived status, so the test can beadministered in the more than 100,000 CLIA waived doctors' offices in theU.S., as well as in any non-waived laboratory.
In addition to the planned acquisition of ThyroTest®, the newsletterreviews agreement with LETI Laboratories, a Barcelona-basedbiopharmaceutical company that operates with exclusive distributors incountries across Europe, to serve as the sole importer of CLX's subsidiaryproducts into the European market. As Master Distributor for CLX products,LETI Laboratories will provide product support and product packagingcontrol; coordinate sales to other European distributors; distribute thecompany's products in Spain and Portugal; act as the registered EUrepresentative for CE marked products; serve as the one point of entry forCLX products into Europe; and assist with the development andimplementation of pricing structures.
In the place of a CEO Greeting, a CEO Question and Answer featuring VeraLeonard that was recently posted to the CLX Medical website has beenincluded in the newsletter.
"The announcement of ThyroTest® as the targeted acquisition for CLX andthe selection of LETI Laboratories to serve as the sole importer of CLX'ssubsidiary products into the European market are both milestone events forthe company, and we are pleased to have the opportunity to review them inour investor newsletter," stated Ms. Leonard. "As important as theseannouncements are, we expect additional significant events to follow, andwe hope that shareholders will continue to monitor the evolving story ofCLX Medical."
To sign up to receive information by email directly from CLX Medical, Inc.when new press releases, investor newsletters, SEC filings, or otherinformation is disclosed, please visithttp://www.clxinvestments.com/email.php.
About CLX Medical, Inc.
CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest inZonda, Inc. (www.zondaincusa.com), which has developed several rapid pointof care tests for medical and non-medical markets, including a rapid testfor Chlamydia. CLX recently announced a letter of intent to acquireThyroTest®, a rapid thyroid stimulating hormone (TSH) screening deviceused for the detection of hypothyroidism in adults, a common thyroiddisease. CLX Medical is focused on the successful worldwide distributionof these and any additional products it may acquire or license.
All statements included in this release, including statements regardingpotential future plans and objectives of CLX Medical, Inc. areforward-looking statements. Such statements are necessarily subject torisks and uncertainties, some of which are significant in scope and naturebeyond CLX Medical's control. There can be no assurance that suchstatements will prove accurate. Actual results and future events coulddiffer materially from those anticipated in such statements depending onmany factors. Historical results are not necessarily indicative of futureperformance.
Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact
